| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Obiltoxaximab Basic information |
| Product Name: | Obiltoxaximab | | Synonyms: | Obiltoxaximab;Research Grade Obiltoxaximab (DXX00401);Research Grade Obiltoxaximab | | CAS: | 1351337-07-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Obiltoxaximab Structure]() |
| | Obiltoxaximab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Obiltoxaximab Usage And Synthesis |
| Enzyme inhibitor | This anti-anthrax therapeutic (MW = 145.5 kDa; CAS 1351337-07-9; Trade Name = Anthim) is an FDA-approved mouse/human chimeric monoclonal antibody that binds to protective antigen (Kd = 0.3 nM), blocking the latter’s interaction with host cell anthrax receptor, which mediates the translocation of lethal factor [LF] and edema factor into the host cell cytoplasm (See Anthrax Lethal Toxin). Anthim is recommended for the treatment (when combined with antibacterial drugs, such as levofloxacin, ciprofloxacin and doxycycline) and prophylactically (when used alone) treat inhalational anthrax (i.e., exposure to Bacillus anthracis spores. Obiltoxaximab was been designed to neutralize the free protective antigen of B. anthracis, thereby inhibiting the lethal effects of anthrax toxins. Inasmuch as it would be unethical to conduct clinical trials in humans with clinically inducced inhalational anthrax, Anthim’s efficacy was evaluated in NZW rabbits and cynomolgus macaques. See also JMV 390-1 |
| | Obiltoxaximab Preparation Products And Raw materials |
|